Rashtriya Newsflash

DelveInsight’s “Osteosarcoma Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 32+ pipeline drugs in the Osteosarcoma pipeline landscape. It covers the Osteosarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Osteosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Osteosarcoma Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/osteosarcoma-pipeline-insight

Key Takeaways from the Osteosarcoma Pipeline Report

• On May 22, 2026- M.D. Anderson Cancer Center initiated a phase II trial studies how well autologous tumor-infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed).
• On May 19, 2026, St. Jude Children’s Research Hospital conducted a phase I study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm.
• On May 15, 2026, Merck Sharp & Dohme LLC announced a phase 1/2 study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
• DelveInsight’s Osteosarcoma Pipeline report depicts a robust space with 25+ active players working to develop 32+ pipeline therapies for Osteosarcoma treatment.
• The leading Osteosarcoma Companies such as Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.
• Promising Osteosarcoma Therapies such as Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide and others.

Want to know which companies are leading innovation in Osteosarcoma? Dive into the full pipeline insights @ Osteosarcoma Clinical Trials Assessment

The Osteosarcoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Osteosarcoma Pipeline Report also highlights the unmet needs with respect to the Osteosarcoma.

Osteosarcoma Overview

Osteosarcoma, or osteogenic sarcoma, is the most common primary malignant bone tumor, accounting for approximately 20% of all cases. Osteosarcoma demonstrates a bimodal age distribution and most commonly occurs in the extremities. Osteosarcoma derived from primitive osteoid-producing mesenchymal cells manifests heterogeneously; the degree of differentiation, location within the bone, and histological variation determine each osteosarcoma subtype. Each subtype varies in demographic distribution, biological behavior, and radiological appearance. High-grade conventional intramedullary osteosarcoma is the most common subtype. This subtype is a biologically complex and aggressive tumor involving a long bone’s metaphysis, usually adjacent to a physis with the most significant growth, such as the proximal humerus, distal femur, or proximal tibia. Osteosarcoma signs and symptoms most often start in a bone. The cancer most often affects the long bones of the legs, and sometimes the arms. The most common symptoms include: Bone or joint pain, pain related to a bone that breaks for no clear reason and swelling near bone.

Osteosarcoma Emerging Drugs Profile

• HS-20093: Hansoh BioMedical R&D Company

HS-20093 (Risvutatug rezetecan) is a B7-H3-targeted antibody-drug conjugate (ADC) developed by Hansoh Pharmaceutical and licensed to GSK. It comprises a humanized anti-B7-H3 IgG1 antibody linked to a topoisomerase I inhibitor (TOPOi) payload. Its mechanism of action (MOA) involves binding to B7-H3 on tumor cells, followed by endocytosis and intracellular cleavage, releasing the cytotoxic payload to cause DNA damage, apoptosis, and potential “”bystander effects”” on surrounding tumor cells. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Osteosarcoma.

• Vactosertib: MedPacto, Inc.

Vactosertib (TEW-7197), a TGF-β1 kinase inhibitor, promotes the cancer cell killing activity of immune cells, and inhibits proliferation of cancer stem cells, angiogenesis and metastasis. In addition, vactosertib can support various cancer treatments to attack cancer cells by suppressing stroma formation. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Osteosarcoma.

• DIT-309: Tcelltech Inc.

DIT-309 (TX-103) is an autologous CAR-T cell therapy developed by Tcelltech for the treatment of neoplasms and nervous system diseases. The mechanism of action (MOA) centers on the use of 4-1BBL-OX40L technology to enhance the efficacy of the T cells. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Osteosarcoma

If you’re tracking ongoing Osteosarcoma Clinical trials, this press release is a must-read @ Osteosarcoma Treatment Drugs

Osteosarcoma Companies

Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics and others.

Osteosarcoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Osteosarcoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Osteosarcoma Pipeline Report covers it all @ Osteosarcoma Market Drivers and Barriers, and Future Perspectives

Scope of the Osteosarcoma Pipeline Report

• Coverage- Global
• Osteosarcoma Companies- Zentalis Pharmaceuticals, MedPacto, Salarius Pharmaceuticals, NextPoint Therapeutics, Base Therapeutics, EMD Serono, Hansoh BioMedical R&D Company, Cellectar Biosciences, OS Therapies, AlaMab Therapeutics, and others.
• Osteosarcoma Therapies- Ceralasertib, Avelumab, Vactosertib, ZN-c3, Gemcitabine, Lenvatinib, Ifosfamide, Etoposide, and others.
• Osteosarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Osteosarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Osteosarcoma Treatment landscape in this detailed analysis @ Osteosarcoma Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Osteosarcoma: Overview
4. Osteosarcoma Pipeline Therapeutics
5. Osteosarcoma Therapeutic Assessment
6. Osteosarcoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HS-20093: Hansoh BioMedical R&D Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. NPX267: Nextpoint Therapeutics
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Osteosarcoma Key Companies
18. Osteosarcoma Key Products
19. Osteosarcoma- Unmet Needs
20. Osteosarcoma- Market Drivers and Barriers
21. Osteosarcoma- Future Perspectives and Conclusion
22. Osteosarcoma Analyst Views
23. Osteosarcoma Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight